Kiniksa Pharmaceuticals (KNSA) Stock Forecast & Price Target

Compare

550 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

KNSA Analyst Ratings

Strong Buy

6 Buy

0 Hold

0 Sell

Based on 6 analysts giving stock ratings to

Kiniksa

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

KNSA Stock 12 Month Forecast

Average Price Target

$57.67

▲(24.02% Upside)

Based on 6 Wall Street analysts offering 12 month price targets for Kiniksa Pharmaceuticals in the last 3 months. The average price target is $57.67 with a high forecast of $68.00 and a low forecast of $50.00. The average price target represents a 24.02% change from the last price of $46.50.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"19":"$19","44":"$44","69":"$69","31.5":"$31.5","56.5":"$56.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":68,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$68.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":57.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$57.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$50.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[19,31.5,44,56.5,69],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,46,47.69230769230769,49.38461538461539,51.07692307692308,52.76923076923077,54.46153846153846,56.15384615384615,57.84615384615385,59.53846153846154,61.230769230769226,62.92307692307692,64.61538461538461,66.3076923076923,{"y":68,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,46,46.89769230769231,47.79538461538461,48.69307692307692,49.59076923076923,50.488461538461536,51.386153846153846,52.283846153846156,53.181538461538466,54.07923076923077,54.97692307692308,55.87461538461538,56.77230769230769,{"y":57.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,46,46.30769230769231,46.61538461538461,46.92307692307692,47.23076923076923,47.53846153846154,47.84615384615385,48.15384615384615,48.46153846153846,48.76923076923077,49.07692307692308,49.38461538461539,49.69230769230769,{"y":50,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":20.28,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.77,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.74,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.92,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.24,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.98,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.28,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.64,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.01,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.93,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.25,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.67,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$68.00

Average Price Target$57.67

Lowest Price Target$50.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Anupam Rama

J.P. Morgan

$68

Buy

46.24%

Upside

Reiterated

03/13/26

Analysts Offer Insights on Healthcare Companies: CareCloud (NASDAQ: CCLD) and Kiniksa Pharmaceuticals (NASDAQ: KNSA)

Edward Nash

Canaccord Genuity

$62

Buy

33.33%

Upside

Reiterated

02/26/26

Analysts' Top Healthcare Picks: Acadia Healthcare (ACHC), Kiniksa Pharmaceuticals (KNSA)

Eva Fortea Verdejo

Wells Fargo

$50→$53

Buy

13.98%

Upside

Reiterated

02/25/26

Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (NASDAQ: IOVA), BioMarin Pharmaceutical (NASDAQ: BMRN) and Kiniksa Pharmaceuticals (NASDAQ: KNSA)

David Nierengarten

Wedbush

$50→$53

Buy

13.98%

Upside

Reiterated

02/24/26

Kiniksa price target raised to $53 from $50 at WedbushKiniksa price target raised to $53 from $50 at Wedbush

Nicholas Lorusso

TD Cowen

$60

Buy

29.03%

Upside

Reiterated

02/24/26

Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (NASDAQ: BEAM), Protara Therapeutics (NASDAQ: TARA) and Kiniksa Pharmaceuticals (NASDAQ: KNSA)

Geoff Meacham

Citi

$50

Buy

7.53%

Upside

Reiterated

01/30/26

Citi Sticks to Its Buy Rating for Kiniksa Pharmaceuticals (KNSA)

Roger Song

Jefferies

$58

Buy

24.73%

Upside

Reiterated

11/18/25

Kiniksa Pharmaceuticals (KNSA) Receives a Buy from Jefferies

Paul Choi

Goldman Sachs

$45→$55

Buy

18.28%

Upside

Reiterated

10/29/25

Goldman Sachs Keeps Their Buy Rating on Kiniksa Pharmaceuticals (KNSA)

Liisa Bayko

Evercore ISI

$35

Buy

-24.73%

Downside

Reiterated

05/12/25

Kiniksa Pharmaceuticals (KNSA) Receives a Buy from Evercore ISI

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Anupam Rama

J.P. Morgan

$68

Buy

46.24%

Upside

Reiterated

03/13/26

Analysts Offer Insights on Healthcare Companies: CareCloud (NASDAQ: CCLD) and Kiniksa Pharmaceuticals (NASDAQ: KNSA)

Edward Nash

Canaccord Genuity

$62

Buy

33.33%

Upside

Reiterated

02/26/26

Analysts' Top Healthcare Picks: Acadia Healthcare (ACHC), Kiniksa Pharmaceuticals (KNSA)

Eva Fortea Verdejo

Wells Fargo

$50→$53

Buy

13.98%

Upside

Reiterated

02/25/26

Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (NASDAQ: IOVA), BioMarin Pharmaceutical (NASDAQ: BMRN) and Kiniksa Pharmaceuticals (NASDAQ: KNSA)

David Nierengarten

Wedbush

$50→$53

Buy

13.98%

Upside

Reiterated

02/24/26

Kiniksa price target raised to $53 from $50 at WedbushKiniksa price target raised to $53 from $50 at Wedbush

Nicholas Lorusso

TD Cowen

$60

Buy

29.03%

Upside

Reiterated

02/24/26

Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (NASDAQ: BEAM), Protara Therapeutics (NASDAQ: TARA) and Kiniksa Pharmaceuticals (NASDAQ: KNSA)

Geoff Meacham

Citi

$50

Buy

7.53%

Upside

Reiterated

01/30/26

Citi Sticks to Its Buy Rating for Kiniksa Pharmaceuticals (KNSA)

Roger Song

Jefferies

$58

Buy

24.73%

Upside

Reiterated

11/18/25

Kiniksa Pharmaceuticals (KNSA) Receives a Buy from Jefferies

Paul Choi

Goldman Sachs

$45→$55

Buy

18.28%

Upside

Reiterated

10/29/25

Goldman Sachs Keeps Their Buy Rating on Kiniksa Pharmaceuticals (KNSA)

Liisa Bayko

Evercore ISI

$35

Buy

-24.73%

Downside

Reiterated

05/12/25

Kiniksa Pharmaceuticals (KNSA) Receives a Buy from Evercore ISI

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Kiniksa Pharmaceuticals

3 Months

xxx

Success Rate

9/10 ratings generated profit

Average Return

+17.25%

reiterated a xxx

rating 22 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 90.00% of your transactions generating a profit, with an average return of +17.25% per trade.

1 Year

Eva Fortea VerdejoWells Fargo

Success Rate

10/10 ratings generated profit

Average Return

+56.87%

reiterated a buy rating 22 days ago

Copying Eva Fortea Verdejo's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +56.87% per trade.

2 Years

xxx

Success Rate

10/10 ratings generated profit

Average Return

+81.57%

reiterated a xxx

rating 22 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +81.57% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

KNSA Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, KNSA has received 44 Buy Ratings, 35 Hold Ratings, and 0 Sell Ratings. KNSA average Analyst price target in the past 3 months is 57.67.

Each month's total comprises the sum of three months' worth of ratings.

KNSA Financial Forecast

KNSA Earnings Forecast

Next quarter’s earnings estimate for KNSA is $0.21 with a range of $0.14 to $0.36. The previous quarter’s EPS was $0.17. KNSA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year KNSA has Performed in-line its overall industry.

KNSA Sales Forecast

Next quarter’s sales forecast for KNSA is $207.12M with a range of $201.02M to $212.91M. The previous quarter’s sales results were $202.13M. KNSA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year KNSA has Performed in-line its overall industry.

KNSA Stock Forecast FAQ

What is KNSA’s average 12-month price target, according to analysts?

Based on analyst ratings, Kiniksa Pharmaceuticals’s 12-month average price target is 57.67.

What is KNSA’s upside potential, based on the analysts’ average price target?

Kiniksa Pharmaceuticals has 24.02% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is KNSA a Buy, Sell or Hold?

Kiniksa Pharmaceuticals has a consensus rating of Strong Buy which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.

What is Kiniksa Pharmaceuticals’s price target?

The average price target for Kiniksa Pharmaceuticals is 57.67. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $68.00 ,the lowest forecast is $50.00. The average price target represents 24.02% Increase from the current price of $46.5.

What do analysts say about Kiniksa Pharmaceuticals?

Kiniksa Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of KNSA?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Kiniksa Pharmaceuticals (KNSA) Stock Forecast & Price Target

KNSA Analyst Ratings

KNSA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Kiniksa Pharmaceuticals

KNSA Analyst Recommendation Trends

KNSA Financial Forecast

KNSA Earnings Forecast

KNSA Sales Forecast

KNSA Stock Forecast FAQ

Detailed List of Analyst Forecasts